
Oral anticoagulant drug considerations in Cancer: Dr Tzu-Fei Wang
In this episode of Clot Conversations, Dr. Tzu-Fei Wang, Ottawa, shares a summary of her presentations at the 2025 ISTH meeting on recent studies on drug interactions in prostate cancer therapy and the use of anticoagulants. Dr Wang also highlights the significance of the WAVe study in assessing dalteparin use without the traditional dose cap in patients over 90 kg. These findings offer reassurance to clinicians prescribing anticoagulation therapy, minimizing previous concerns. The discussion provides optimism for improved cancer care protocols, showcasing safer, more effective anticoagulation practices for patients..
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Altri episodi di "CLOT Conversations"
Non perdere nemmeno un episodio di “CLOT Conversations”. Iscriviti all'app gratuita GetPodcast.